The Economic Times daily newspaper is available online now.

    Rakesh Jhunjhunwala, LIC hiked stake in this pharma company in Q2

    Synopsis

    Total holdings of mutual fund houses in the company also increased to 12.58 per cent from 11.94 per cent on a quarter-on-quarter basis, data available with BSE showed on Tuesday.

    Pharma-1---APAP
    Overall, analysts are positive on the pharmaceutical sector due to steady earnings visibility going ahead.
    NEW DELHI: Country’s biggest institutional investors Life Insurance Corporation of India and ace equity investor Rakesh Jhunjhunwala lapped up additional shares in pharmaceutical firm Lupin during the July-September quarter.

    The latest shareholding data revealed that Jhunjhunwala held 69,45,605 shares, or 1.53 per cent stake, in the company as of September 30 against 66,45,605 shares or 1.47 per cent stake owned by him in the June quarter.

    On the other hand, LIC’s stake increased to 3.71 per cent from 2.70 per cent during the same period.

    Shares of the company traded 2.33 per cent down at Rs 1,032 at around 2.15 pm (IST) on Wednesday, while the benchmark BSE Sensex traded 0.49 per cent lower at 40,426.

    Total holdings of mutual fund houses in the company also increased to 12.58 per cent from 11.94 per cent on a quarter-on-quarter basis, data available with BSE showed on Tuesday.
    « Back to recommendation stories
    I don't want to see these stories because
    SUBMIT

    On a year-to-date basis, Lupin shares have gained 38 per cent while Sensex has retreated 1.52 per cent.

    Brokerage firm Prabhudas Lilladher is positive on the stock with a target price of Rs 1,085.

    “We remain upbeat of Lupin on regulatory revival theme and new launches in the US market,” the brokerage said.

    In the recent update, Lupin last week said it has received approval from the US health regulator to market generic Dimethyl Fumarate delayed-release capsules used for the treatment of relapsing forms of multiple sclerosis in adults.

    The company has received approval from the United States Food and Drug Administration (USFDA) to market its Dimethyl Fumarate delayed-release capsules in the strengths of 120 mg and 240 mg, Lupin said in a statement.

    Overall, analysts are positive on the pharmaceutical sector due to steady earnings visibility going ahead.

    According to ICICI Prudential AMC, pharma sector may do well due to its critical nature post Covid-19. “Earnings visibility is high and the sector is also a good defensive play in times of volatility,” the mutual fund house said.



    (What's moving Sensex and Nifty Track latest market news, stock tips and expert advice, on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds .)

    Download The Economic Times News App to get Daily Market Updates & Live Business News.

    Subscribe to The Economic Times Prime and read the Economic Times ePaper Online.and Sensex Today.

    Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price

    ...more


    (What's moving Sensex and Nifty Track latest market news, stock tips and expert advice, on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds .)

    Download The Economic Times News App to get Daily Market Updates & Live Business News.

    Subscribe to The Economic Times Prime and read the Economic Times ePaper Online.and Sensex Today.

    Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price

    ...more
    The Economic Times

    Stories you might be interested in